Scientific and Medical Equipment House Valuation
Is 4014 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4014 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4014 (SAR51.6) is trading below our estimate of fair value (SAR1229.48)
Significantly Below Fair Value: 4014 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4014?
Key metric: As 4014 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4014's PE Ratio? | |
|---|---|
| PE Ratio | 36.6x |
| Earnings | ر.س42.31m |
| Market Cap | ر.س1.55b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.8x |
| Enterprise Value/EBITDA | 20.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 4014's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29.8x | ||
9518 Canadian General Medical Center Complex | 49.5x | n/a | ر.س548.2m |
9546 Naba Al Saha Medical Services | 22.3x | n/a | ر.س840.0m |
9530 Arabian International Healthcare Holding | 27.9x | n/a | ر.س831.2m |
9527 Alf Meem Yaa for Medical Supplies and Equipment | 19.5x | n/a | ر.س739.2m |
4014 Scientific and Medical Equipment House | 36.6x | n/a | ر.س1.5b |
Price-To-Earnings vs Peers: 4014 is expensive based on its Price-To-Earnings Ratio (36.6x) compared to the peer average (29.8x).
Price to Earnings Ratio vs Industry
How does 4014's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 4014 is expensive based on its Price-To-Earnings Ratio (36.6x) compared to the Asian Healthcare industry average (21.2x).
Price to Earnings Ratio vs Fair Ratio
What is 4014's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 36.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4014's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.